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Abstract
Introduction Comparison of intra-articular bacterial-derived
hyaluronic acid (Hyalubrix®) (HA) with local analgesia
(mepivacaine) for osteoarthritis (OA) of the hip.
Methods A pilot prospective, double-blind, 6-month
randomized trial of 42 patients with hip OA. HA or mepivacaine
was administered twice (once a month) under ultrasound
guidance. Efficacy measurements included the Lequesne's
algofunctional index, a visual analog scale for pain, concomitant
use of analgesia, patient and physician global measurement, and
safety.
Results Patients in the HA group exhibited a significantly
reduced Lequesne's algofunctional index 3 and 6 months after
treatment (P < 0.001) and significantly reduced visual analog
scale pain scores 3 and 6 months after treatment (P < 0.05)
compared with the local anesthetic group. All primary and
secondary measures were significantly improved versus
baseline, but other than the above were not different from each
other at 3 or 6 months. Adverse effects were minimal.
Conclusions This comparative study suggests a beneficial
effect and safety of intra-articular HA in the management of hip
OA.
Trial registration number ISRCTN39397064.
Introduction
Osteoarthritis (OA) is the most common joint disorder; with a
calculated prevalence of 10 to 18% in the United States [1].
OA of the hip is second to the knee in frequency, with preva-
lence in white men of 17% and in white women of 9%, for
those 60 years or older [1,2]. Within 10 years of the onset of
hip OA, 30 to 50% will result in total hip replacement. As
reported in the studies, 'The National Arthritis Data Workgroup
reviewed data from available surveys, such as the National
Health and Nutrition Examination Survey series. For overall
national estimates, we used surveys based on representative
samples' [1,2]. In these cited studies, clinical and radiological
parameters were observed for extracting numerical data about
the prevalence of OA.
Contemporary management of hip OA is directed at pain con-
trol, improvement function and improved health-related quality
of life. Management of hip OA includes nonpharmacological
modalities (patient education, exercise, assistive devices, and
weight management) and pharmacological treatments ranging
from oral to intra-articular (IA) therapy. Oral therapy consists of
analgesics and nonsteroidal anti-inflammatory drugs
(NSAIDs), both with attendant risks [3-6]. There is limited
information on IA therapy, such as depocorticosteroids [7] and
hyaluronate (hyaluronic acid (HA), hyaluronan) [8].
HA: hyaluronic acid; IA: intra-articular; NSAID: nonsteroidal anti-inflammatory drug; OA: osteoarthritis; VAS: visual analog scale.Arthritis Research & Therapy    Vol 11 No 6    Migliore et al.
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In addition to establishing the safety of HA treatment, many
studies on OA of the knee have demonstrated good efficacy
profiles for IA HA treatments [9-12]. IA HA appears to be an
ideal treatment for patients with knee OA with persistent pain
that does not respond to conservative treatment, or for
patients that are not possible candidates for joint replacement
due to clinical conditions that make surgical replacement
impossible to perform. Although IA HA generally has a slower
onset of action than IA steroids, the therapeutic effect of IA HA
injection appears to last longer [13].
Hyalubrix® is a sterile nonpyrogenic solution of HA sodium salt
(15 mg/ml sodium HA) with a molecular-weight range of 1,500
to 3,200 kDa. Although biochemically processed similar to
Hyalgan®, it is produced by bacterial fermentation. It has been
used in the treatment of knee OA, and a postmarketing study
on 1,523 patients supported the efficacy and safety of Hyalu-
brix® in pain reduction and functional improvement in the knee
[14].
In comparison with HA, IA local anesthetics (for example,
mepivacaine) are analgesic with potential therapeutic proper-
ties such as dilution of proinflammatory cytokines in patholog-
ical synovial fluid and reduction of neuro-mediated
inflammation by the inhibition of neuropeptide production.
These latter actions appear to last longer than the analgesic
effect [15-17].
Our previous studies [18,19], as well as other studies [20,21],
suggested good efficacy profiles for IA HA treatments in hip
OA as well as good safety profiles for such treatment when
performed under ultrasound guidance.
The present pilot study compared the benefit, duration and
adverse event profile of IA Hyalubrix® versus IA mepivacaine,
in the treatment of hip OA using ultrasound guidance to
ensure IA injection [18].
Materials and methods
Study design
The study was a single-site, prospective, randomized, double-
blind, controlled clinical trial of the efficacy and safety of ultra-
sound-guided IA HA (Hyalubrix®, Fidia S.p.A, Padova, Italy)
versus an IA analgesic (Mepivacaine, Fidia S.p.A, Padova,
Italy) in outpatients with hip OA once a month for two injec-
tions. The patients and examiner were not aware of the
injected drug. A separate unblinded investigator performed
the injections.
The study protocol, including informed consent documenta-
tion, insurance, and Summary of Product Characteristics, was
approved by the hospital ethics committee and the study fol-
lowed the guidelines of the Declaration of Helsinki.
All patients were examined at baseline, completed the
Lequesne algofunctional index (grades 1 to 4), recorded hip
pain on a 10 cm visual analog scale (VAS), and recorded a
patient's global assessment score for hip OA. The translation
of the question asked was: 'How important do you think your
hip osteoarthritis is for your global quality of life?'. A physi-
cian's global score was also assessed at baseline (how impor-
tant the physician thinks the hip OA is for global life quality of
the patient, with a range of 0 to 10). Baseline information
included NSAID consumption by the number of days in the
prior month in which NSAIDs were used (range 0 to 30), plus
the number of NSAIDs taken per day.
Consecutive patients with hip OA were randomly assigned to
receive Hyalubrix® or mepivacaine by a computer-generated
block randomization schedule. The study included 42 patients,
20 women and 22 men.
Inclusion criteria included the following: age >40 years; ambu-
lant without assistance; hip OA by American College of Rheu-
matology radiographic criteria; baseline VAS ≥ 4 cm;
persistence of hip pain for at least 1 month before baseline;
and signed informed consent.
Exclusion criteria were as follows: comorbidities (for example,
rheumatoid arthritis, avascular necrosis, fibromyalgia); infec-
tion around the injection site; treatment with oral, parenteral, or
IA steroids within 3 months; use of anticoagulants or history of
thrombocytopenia; allergy to local anesthetics; history of
adverse reaction to IA HA; pending hip replacement surgery;
and use of a purported OA disease-modifying agent.
The primary endpoint of the present study was the determina-
tion of the change in the Lequesne index of the hip, comparing
IA HA with IA mepivacaine at 26 weeks. Secondary endpoints
were pain intensity (recorded on a 10 cm VAS), patient record
of NSAID consumption, patient's global assessment, examin-
ing physician's global assessment, demographic correlations
to response, and HA safety.
All adverse events were recorded with a question of severity,
in relation to therapy and graded by severity. Measurements
were recorded at screening, baseline, 3 months after the first
injection, and 6 months after the first injection. Safety informa-
tion was collected and reported on the basis sponsor's stand-
ard operating procedures, the international conference on
harmonization of good clinical practice and the applicable Ital-
ian regulatory requirements.
Treatment
IA hip injections were guided by ultrasound using an antero-
sagittal approach [18,19]. The assistance of real-time ultra-
sound and Doppler imaging avoided vessel injection and vali-
dated penetration of the hip joint. Ultrasonography alsoAvailable online http://arthritis-research.com/content/11/6/R183
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provided information on joint features, OA severity, detection
of bursitis, synovial effusion, and IA-free bodies [18].
Each of the two treatment sessions consisted of an IA injection
of either HA 4 ml (two syringes, 60 mg) or 2% mepivacaine 4
ml. Hyalubrix® is a sterile, nonpyrogenic, viscoelastic solution
manufactured with HA sodium salt obtained by bacterial fer-
mentation from a fraction of high molecular weight (>1,500
kDa). Mepivacaine 2%, a local anesthetic, is a sterile isotonic
solution manufactured with mepivacaine hydrochloride 20 mg/
ml. For the IA injection, the patient was supine with the hip
internally rotated 15 to 20°. A 3.5-MHz convex transducer
(MyLab25, Esaote, Genova, Italy) fitted with a sterile biopsy
guide was used to perform ultrasound guidance. The hip joint
was examined by ultrasound using an antero-para-sagittal
approach, lateral with respect to femoral vessels defined by
color Doppler imaging. The guide was aligned with the long
axis of the femoral neck, including the femoral head and the
acetabulum. The IA injection was performed by inserting a 20-
guage, 0.9 × 90 mm spinal needle into the biopsy guide.
Under real-time guidance, the needle was advanced into the
anterior capsular recess at the level of the femoral head. After
contact with the femoral head, the needle was retracted 1 mm.
The medication solution was injected, and the IA localization
was monitored by real-time ultrasound visualization and Dop-
pler signal.
Statistical analysis
All treated patients were considered for statistical analysis. No
subsets of patients were evaluated. Statistical analyses were
performed on changes or on absolute values, as applicable, at
a 5% level of significance. Analyses were performed using
SPSS software (IBM corporation, Armonk, NY, USA).
Descriptive statistics were calculated on the basis of demo-
graphic and clinical data at baseline. Data were described by
the mean, median, standard deviation, range, and frequency.
Demographic and clinical data of treatment groups were com-
pared at baseline by a chi-square test or a t test.
All efficacy variables were analyzed with tests for repeated
measures. Differences in VAS pain, NSAID intake, days of
intake of NSAIDs in the past month, and global assessment
were investigated by an analysis of the variance for repeated
measures, whereas differences in Lequesne's algofunctional
index were analyzed by a Wilcoxon test. Adverse events that
occurred during the study were listed individually.
Results
Patients' characteristics are presented in Table 1. There were
no differences between groups; in the global population, the
mean age was 70 ± 8.9 years with an age range of 42 to 79
years, the mean height was 171 ± 7.4 cm, and the mean body
mass index was 25.7 ± 3.2. Patients were affected by gener-
alized OA (45%), idiopathic hip OA (95.5%), and localized hip
OA (55%). The most frequent Kellgren-Lawrence radiological
grade was 3 (85.7%); it was grade 4 in two cases, both rand-
omized to the local anesthetic group.
There were eight (19%) discontinuations, five in the Hyalu-
brix® treatment group and three in the mepivacaine group (Fig-
ure 1), there was one treatment failure per group, and four
patients were lost to follow up or retracted their consent to
participate. Two patients were not evaluated for the 6-month
follow-up visit since comorbidities appearing in the fourth
month of the study made correct and exact evaluation of pri-
mary and secondary study endpoints impossible; in particular,
one patient reported Herpes Zoster virus infection and a need
for NSAIDs for symptom control, and one patient reported
intense pain for valgus hallux that strongly increased the
Lequesne index value and NSAID consumption, both in the
Hyalubrix® group.
Lequesne's algofunctional index
Both treatment groups improved versus baseline at 3 and 6
months (P < 0.001). HA was superior to mepivacaine at 3
months (P < 0.001) and at 6 months (P < 0.05) (Table 2 and
Figure 2).
Secondary outcomes
Pain intensity
Both groups improved versus baseline at 3 and 6 months (P
< 0.001) in both groups (Table 3). HA was superior to mepi-
vacaine for the VAS at 3 and 6 months (P < 0.05).
Nonsteroidal anti-inflammatory drug intake
Both groups improved at 3 and 6 months versus baseline (P
< 0.001), with no statistically significant differences between
treatment groups (Table 3). Even if statistical significance was
not reached when comparing results from the Hyalubrix® and
local anesthetic groups, the reduction in NSAID intake was
49.4% after 3 months in the Hyalubrix® group and 24.6% in
the local anesthetic group.
Global assessment
Similar to the change in NSAID intake, there was a significant
reduction in patient and physician global assessment from
baseline at both 3 and 6 months in both groups (P < 0.001),
without significance differences between treatment groups
(Table 3).
Tolerability
Two adverse events were reported during the treatment
phase. One HA-treated patient experienced moderate hip pain
after the second injection that resolved within 7 days of treat-
ment with paracetamol 2 g/day. One mepivacaine-treated
patient had mildly intense injection site pain after the first injec-
tion, which lasted 36 hours without therapy after the second
injection.
No serious adverse events were reported during the study.Arthritis Research & Therapy    Vol 11 No 6    Migliore et al.
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Discussion
The present report describes the first comparative, prospec-
tive, double-blind, and randomized study comparing the safety
and efficacy of Hyalubrix® with local anesthetic in symptomatic
hip OA. The variables registered during the trial were the
Lequesne's algofunctional index, the VAS pain score, NSAID
intake, and patient's and physician's global assessment as
suggested by Outcome Measures in Rheumatoid Arthritis
Clinical Trials-Osteoarthritis Research Society International
criteria [20]. Of the 42 patients enrolled in the study, the most
frequent Kellgren-Lawrence radiological grade was grade 3
(85.7%), and the severest grade 4 was present only in two
Table 1
Patients' characteristics: demographical, physical and clinical information about patients in study.
Characteristic Hyalubrix® group (n = 22) Carbocaine group (n = 20) Global population (n = 42)
Males 12 10 22
Females 10 10 20
Smokers 4 2 6
Age 68 ± 10.3 67 ± 7.2 70 ± 8.9
Age range 44 to 79 42 to 77 42 to 79
Height 170 ± 6.9 172 ± 8.0 171 ± 7.4
Body mass index 25.6 ± 2.2 24.8 ± 4.1 25.7 ± 3.2
Hip osteoarthritis
Unilateral right 6 (27.3%) 12 (60.0%) 18 (42.8%)
Unilateral left 4 (18.2%) 1 (5.0%) 5 (10.4%)
Bilateral 12 (54.5%) 7 (35.0%) 19 (45.2%)
Type
Primary 21 (95.5%) 17 (85.0%) 38 (90.5%)
Secondary 1 (4.5%) 3 (15.0%) 4 (9.5%)
Systemic osteoarthritis
Yes 11 (50.0%) 8 (40.0%) 19 (45.2%)
No 11 (50.0%) 12 (60.0%) 23 (54.8%)
Duration of osteoarthritis (years)
Mean 4 5.5 4.71
Median 3.5 3.5 3.5
Standard deviation 2.87 5.1 3.93
Minimum 1 1 1
Maximum 10 20 20
Radiological gradea
2 1 (4.5%) 3 (15.0%) 4 (9.5%)
3 21 (95.5%) 15 (75.0%) 36 (85.7%)
4 - 2 (10.0%) 2 (4.8%)
Knee osteoarthritis
Absent 12 (54.5%) 12 (60.0%) 24 (57.1%)
Unilateral right 1 (4.5%) 1 (5.0%) 2 (4.8%)
Unilateral left 2 (9.1%) 1 (5.0%) 3 (7.1%)
Bilateral 7 (31.8%) 6 (30.0%) 13 (31%)
Data presented as n (%) or mean ± standard deviation unless otherwise stated. aDemographical, physical and clinical conditions of patients in 
study were similar among two subgroups.Available online http://arthritis-research.com/content/11/6/R183
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cases. This result illustrates that visco-induction can be effica-
cious even in patients presenting a moderate-severe radiolog-
ical score of hip joint OA.
Although all intra-group differences in efficacy outcomes were
statistically significant compared with baseline, there were no
significant inter-group differences in NSAID intake or patient's
and physician's global assessment at any time during the fol-
low-up. Statistically significant differences between treat-
ments were observed for Lequesne's algofunctional index and
the VAS pain score, with patients enrolled in the Hyalubrix®
group showing improved scores at 3 and 6 months. Further-
more, with respect to the VAS pain score, the results of this
study suggest that pain relief obtained with Hyalubrix® persists
for at least 6 months after treatment.
Clinical studies that have examined the efficacy of HA prod-
ucts for hip OA include two systematic reviews [21,22], two
randomized controlled trials [23,24], and two uncontrolled tri-
als [25,26]. Among the randomized controlled trials, the study
performed by Qvistgaard and colleagues randomized patients
into three treatment groups: HA, corticosteroids, and saline
solution [23]. The authors concluded that corticosteroids
were more effective in relieving pain and improving functional-
ity than HA, which showed good efficacy but did not achieve
statistically significant amelioration of symptoms. In contrast,
our data suggest that IA HA injection has statistically signifi-
cant effects on pain and functionality in hip OA-affected
patients.
This apparent discrepancy might be explained by some differ-
ences between the two studies. First, the follow-up time in our
study was longer (6 months versus 3 months), which could
facilitate the discovery of long-lasting effects of HA-based
therapy. Moreover, Qvistgaard and colleagues administered a
total of 60 mg HA (three injections), whereas we administered
a total of 120 mg HA (two injections). Different doses of HA
might lead to different levels of saturation of CD44 and of
other HA receptors such as hyaloadherins, and this might influ-
ence receptor activation and biological effects [27]. Also, dif-
ferent molecular weights of HA might lead to different efficacy
and safety results. The Hyalubrix® used in this study had a
molecular weight >1,500 kDa, whereas the HA product in
Qvistgaard and colleagues' study had a molecular weight of
500 to 730 kDa. Furthermore, Qvistgaard and colleagues'
compared HA with corticosteroids instead of with local anes-
thetics.
Figure 1
Patients' disposition and study progress Patients' disposition and study progress.
Table 2
Lequesne index values for patients undergoing Hyalubrix® or 
mepivacaine ultrasound-guided intra-articular injection of the 
hip
Patient subgroup Lequesne index
Baseline 3 months 6 months
Hyalubrix® group 7.09 ± 3.78 5.15 ± 5.15a 3.94 ± 2.58a
Mepivacaine group 7.75 ± 4.15 6.53 ± 4.33 6.41 ± 4.14
Data presented as mean ± standard deviation. All values obtained at 
3-month and 6-month control visits reached statistical significance 
when compared with baseline values. aValues obtained at 3 months 
were also significantly different when comparing Hyalubrix® results 
with mepivacaine results in terms of the Lequesne index (P < 0.001); 
at 6 months the significant difference between the two subgroups 
was still present (P < 0.05).Arthritis Research & Therapy    Vol 11 No 6    Migliore et al.
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In the other randomized controlled trial, Tikiz and colleagues
compared the efficacies of IA injections of a lower-molecular-
weight hyaluronan (HA) and of a higher-molecular-weight
visco-supplement in hip OA [24]. No significant differences in
outcomes were found between any of the measurements at
the first, third, and sixth months.
Other studies [25,26,28-33] with a total of 141 participants
treated with one to three injections of Hylan GF20 (Genzyme,
Cambridge, MA, USA), reported an overall success rate of
approximately 50% after 3 to 12 months. These smaller open-
label trials of 10 to 57 participants, without a control group,
generally reported moderate improvements in pain and func-
tion after treatment with Durolane [28], with Ostenil [26,33],
with or Synvisc [25,32]. All studies measured pain (VAS or
numerical pain rating scale) or disability (Western Ontario Mac
Master scale or Lequesne scale). Because there was no con-
trol group and no random allocation, these results must be
interpreted with caution, with greater weight placed on the evi-
dence from systematic reviews and randomized controlled tri-
als.
In the present study, global assessments decreased strongly
for both local anesthetic and Hyalubrix®, and these effects
were more evident after 6 months. This result confirms the
findings of previous studies of hip OA and of knee OA that HA
Figure 2
Lequesne index mean values for subgroups of patients treated with Hyalubrix® or mepivacaine via intra-articular ultrasound-guided injection of the  hip Lequesne index mean values for subgroups of patients treated with Hyalubrix® or mepivacaine via intra-articular ultrasound-guided injection of the 
hip. P < 0.001 for every value obtained at 3 or 6 months for both subgroups when compared with baseline values. p 0.001 was observed also when 
comparing values obtained from the hyalubrix® group with those from the mepivacaine group at 3 months, while P < 0.05 was observed when com-
paring values obtained from the Hyalubrix® group with those from the mepivacaine group at 6 months.
Table 3
Secondary outcome measures obtained for subgroups of patients
Secondary outcome measure Patient subgroup Baseline 3 months 6 months
Pain visual analogic scale Hyalubrix® group 6.4 ± 1.94 4.3 ± 2.58a 4.5 ± 1.96a
Mepivacaine group 6.0 ± 1.34 4.5 ± 2.63 5.0 ± 2.41
NSAID consumption Hyalubrix® group 8.5 ± 3.6 2.1 ± 0.4 1.5 ± 0.5
Mepivacaine group 6.9 ± 2.2 5.5 ± 3.0 2.3 ± 1.0
Global physician assessment Hyalubrix® group 5.5 ± 1.58 4.4 ± 1.49 4.0 ± 1.51
Mepivacaine group 5.1 ± 1.41 4.5 ± 1.61 4.3 ± 1.61
Global patient assessment Hyalubrix® group 6.1 ± 2.07 4.5 ± 2.31 4.0 ± 2.06
Mepivacaine group 5.7 ± 1.68 4.7 ± 2.33 4.9 ± 2.01
All values reached statistical significance when compared with baseline values aPain visual analogic scale showed statistical significance also 
when comparing values obtained in the two subgroups of therapy (P < 0.05). NSAID, nonsteroidal anti-inflammatory drug.Available online http://arthritis-research.com/content/11/6/R183
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visco-supplementation is more effective in the long term [8-
11].
NSAID consumption in NSAID-taking patients decreased from
baseline during the study period. For the group that received
Hyalubrix® therapy, however, the NSAID consumption rate
was higher at baseline than that of patients treated with local
anesthetic. Interestingly, the reduction in NSAID intake was
49.4% after 3 months in the Hyalubrix® group and 24.6% in
the local anesthetic group. An NSAID consumption rate
decrease and a Lequesne index improvement might have eco-
nomic impacts. We hypothesize that a reduction in NSAID
consumption would lead not only to lesser pharmacological
costs for NSAIDs, but also might lead to decreased consump-
tion of other drugs, such as proton pump inhibitors and other
medications needed to counteract side effects of NSAIDs. An
improvement in the Lequesne index might also lead to
improvements in common activities of the patient, such as
work (with productive gain) and self-care (with reduced assist-
ance-related costs). These results encourage pharmacoeco-
nomic studies to establish precisely the cost-effectiveness of
IA treatment in the management of hip OA.
The low incidence of adverse events (<5%) in the present
study of patients undergoing ultrasound-guided IA injection
was similar to the safety results obtained by Tikiz and col-
leagues by fluoroscopic guidance [24], which suggests that
ultrasound guidance achieves successful IA injection of the
medication. Moreover, the ultrasound-guided technique might
be helpful to reduce adverse events related to misplacement
of HA during the injection. In addition, the ultrasound-guided
technique helps reduce radiation exposure for both patients
and clinical operators. The volume of 4 ml drug was well toler-
ated by all patients when injected into the hip joint.
The present study has a couple of limitations. First, the study
did not compare HA treatment with a placebo. The decision to
inject local anesthetic instead of placebo was made for ethical
reasons; the local ethics committee requested a valid treat-
ment for both groups of patients. Furthermore, a placebo that
consists of physiological solution might appear to have a ther-
apeutic effect resulting from the dilution of proinflammatory
cytokines. A true placebo would consist of puncture without
injection of any solution, but for obvious ethical reasons this
experiment could not be performed. Because the present
study showed good efficacy of IA injection of local anesthetic
in the treatment of hip OA, further studies on the efficacy of
this treatment are needed. The number of patients and the fol-
low-up times are sufficient to establish results and significan-
ces, but a larger study population and longer follow-up times
would increase the certainty of results.
Conclusions
The present comparative study and previous reports agree on
the positive effects of IA HA injection in the management of hip
OA. Furthermore, our data suggest that ultrasound-guided
visco-induction should be considered a therapeutic option for
patients affected by hip OA.
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